Ekso Bionics Holdings, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)

9 Months Ended

Sep. 30, 2017

Schedule of Earnings Per Share, Basic and Diluted

The following table sets forth the computation of basic and diluted net loss per share:

	Three months ended				Nine months ended
	September 30,				September 30,
	2017		2016		2017		2016
Numerator:
Net loss applicable to common stockholders
Basic	$	(6,335)	$	(11,494)	$	(20,144)	$	(28,239)
Adjustment for revaluation of warrant liability		-		-		-		(3,030)
Diluted	$	(6,335)	$	(11,494)	$	(20,144)	$	(31,269)

Denominator:
Weighted-average number of shares, basic		34,720		19,005		27,425		16,888
Effect of dilutive warrants		-		-		-		707
Weighted-average numbers of shares, diluted		34,720		19,005		27,425		17,595

Net loss per share, basic	$	(0.18)	$	(0.60)	$	(0.73)	$	(1.67)
Net loss per share, diluted	$	(0.18)	$	(0.60)	$	(0.73)	$	(1.78)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

The following table sets forth potential shares of common stock that are not included in the calculation of diluted net loss per share because to do so would be anti-dilutive as of the end of each period presented:

	Three months ended				Nine months ended
	September 30,				September 30,
	2017		2016		2017		2016
Options to purchase common stock		2,972		2,474		2,972		2,474
Restricted stock		609		-		609		-
Warrants for common stock		3,426		4,085		3,426		1,963
Total common stock equivalents		7,007		6,559		7,007		4,437